A comparison of current neuroblastoma chemotherapeutics

Abstract

Neuroblastoma is the most common solid tumour in childhood. Modern management includes a biopsy to perform genetic studies. Based on clinical data and Myc-N amplification (MNA), patients are divided in three prognostic groups: the low-risk (Stage 1, 2, 4S without MNA) has an event-free survival (EFS) of > 90% with surgery alone; the intermediate-risk (Stage 3, > 1 year of age, without MNA and Stage 3 and 4 infants without MNA) has an EFS of ∼ 80% with mild chemotherapy and surgery; the high-risk group includes Stage 4, > 1 year of age and any stage and age with MNA. These patients are treated with chemotherapy, surgery, megatherapy, irradiation and 13-cis-retinoic acid. With this complex therapy, a 5-year EFS of 30 – 50% can be obtained.

• 13-cis-retinoic
• autologous bone marrow transplantation
• anti-GD2
• chemotherapy
• induction chemotherapy
• metaiodobenzylguanidine-therapy
• neuroblastoma
• prognostic groups
• treatment